Vincristine
Vincristine (Leurocristine) is a microtubule-destabilizing agent (MDA) . Vincristine binds to tubulin and inhibits the formation of microtubules, thereby inhibiting mitosis of the cancer cell. Vincristine is used to research hematologic cancers, such as leukemia and lymphoma, and childhood sarcomas[1][2].
Product Specifications
CAS Number
[57-22-7]
Product Name Alternative
Leurocristine; NSC-67574; 22-Oxovincaleukoblastine
UNSPSC
12352005
Hazard Statement
H315, H319, H320
Target
Antibiotic; Microtubule/Tubulin; Mitosis
Related Pathways
Anti-infection; Cell Cycle/DNA Damage; Cytoskeleton
Applications
Cancer-programmed cell death
Field of Research
Cancer
Purity
98.60
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
CC[C@@]1(C=CCN2CC3)[C@@]2([H])[C@@]3(C4=CC([C@](C5=C6C7=CC=CC=C7N5)(C[C@](C[C@](CC)(O)C8)([H])C[N@@]8CC6)C(OC)=O)=C(OC)C=C4N9C=O)[C@]9([H])[C@](C(OC)=O)(O)[C@@H]1OC(C)=O
Molecular Formula
C46H56N4O10
Molecular Weight
824.96
Precautions
H315, H319, H320
References & Citations
[1]Prota AE, et al. A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs. Proc Natl Acad Sci U S A. 2014 Sep 23;111 (38) :13817-21.|[2]Beaver C, et al. Vincristine Minibag Administration: A Quality Improvement Project to Minimize Medical Errors. Clin J Oncol Nurs. 2018 Dec 1;22 (6) :669-672.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Natural Products
Clinical Information
Launched
Citation 01
Biochem Biophys Res Commun. 2023 Sep 24:674:27-35.|Biomed Pharmacother. 2020 May;125:110003.|bioRxiv. 2023 Apr 14.|bioRxiv. 2023 Feb 27:2023.02.27.530263.|bioRxiv. 2025 Aug 27.|bioRxiv. 2019 Dec.|Breast Cancer Res Treat. 2023 Jul;200 (2) :193-201.|Cancers (Basel) . 2022 Oct 19;14 (20) :5127.|Cell Mol Immunol. 2023 Jan;20 (1) :51-64.|Cell Rep Med. 2025 Oct 21;6 (10) :102401.|Clin Transl Med. 2025 May;15 (5) :e70336.|DRUG RESIST UPDATE. 2023 Feb 13;68:100951.|Front Oncol. 2020 Mar 13;10:308.|Front Pharmacol. 2022 Jul 15:13:931501.|J Biomed Inform. 2023 Jun:142:104383.|J Transl Med. 2023 Jan 9;21 (1) :9.|Mol Pharm. 2022 Nov 7;19 (11) :4320-4332.|Acta Pharmacol Sin. 2021 Jan;42 (1) :108-114.|Acta Pharmacol Sin. 2024 Oct;45 (10) :2174-2185.|Am J Cancer Res. 2021 Apr 15;11 (4) :1428-1445.|bioRxiv. 2023 Jul 25:2023.07.23.550205.|bioRxiv. 2024 Apr 3:2023.06.02.542933.|bioRxiv. 2024 Jul 22:2023.09.14.557413.|bioRxiv. 2024 July 04.|bioRxiv. 2025 Jul 12:2025.07.08.663754.|bioRxiv. 2025 Sep 21.|Br J Cancer. 2024 Oct;131 (7) :1212-1223.|Cairo University. 2025.|Cancer Commun (Lond) . 2024 Apr;44 (4) :469-490.|Cancer Immunol Res. 2023 May 3;11 (5) :583-599.|Cancers (Basel) . 2021 Jul 2;13 (13) :3323.|Cell Biomater. 2025 Jul 22.|Cell Chem Biol. 2020 Nov 19;27 (11) :1359-1370.e8.|Cell Commun Signal. 2024 Jun 13;22 (1) :325.|Cell Death Dis. 2025 Mar 12;16 (1) :170.|Cell Rep Med. 2024 Mar 19;5 (3) :101468.|Cell Rep Med. 2025 Apr 2:102053.|Cell Rep Med. 2025 Apr 25:102098.|Cell. 2024 Apr 25;187 (9) :2288-2304.e27.|Cell. 2025 Oct 24:S0092-8674 (25) 01126-2.|Clin Epigenetics. 2025 May 6;17 (1) :77.|Drug Des Devel Ther. 2025 Feb 7:19:827-840.|Eur J Med Chem. 2018 Feb 25:146:157-170.|Front Microbiol. 2019 May 9:10:939.|Front Oncol. 2021 Apr 22:11:665763.|Front Oncol. 2021 Apr 6.|Front Oncol. 2024 Jul 19:14:1440650.|Hum Exp Toxicol. 2021 Jul;40 (7) :1208-1221.|Ind Crops Prod. 2025 Aug.|Int J Biol Macromol. 2019 May 1:128:574-582.|Int J Nanomedicine. 2017 Mar 16:12:2081-2108.|J Chromatogr B Analyt Technol Biomed Life Sci. 2021 Apr 1:1168:122591.|J Clin Invest. 2024 Mar 7;134 (10) :e172716.|Leuk Lymphoma. 2020 Feb;61 (2) :420-428.|Leukemia. 2021 Oct;35 (10) :2827-2839.|Mol Cancer. 2024 Jan 10;23 (1) :12.|Mol Ther. 2021 Dec 1;29 (12) :3449-3464.|Neurobiol Learn Mem. 2019 Sep:163:107038.|Oncotarget. 2017 Dec 2;8 (68) :112313-112329.|Pharmacol Res. 2024 May 9:204:107208.|PLoS Biol. 2024 Jun 27;22 (6) :e3002672.|Proc Natl Acad Sci U S A. 2022 Aug 30;119 (35) :e2208457119.|Sci Adv. 2023 Feb 10;9 (6) :eade9238.|Sci Rep. 2019 Aug 12;9 (1) :11677.|SLAS Discov. 2024 Feb 12;29 (2) :100147.|SSRN. 2025 Jun 4.
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
![Mouse Monoclonal Collagen VII Antibody (LH7.2) [Alexa Fluor 350]](https://cdn.genprice.uk/genprice/uk/genprice5.webp)
NBP3-08278AF350 100 µL
Mouse Monoclonal Collagen VII Antibody (LH7.2) [Alexa Fluor 350]
Ask
View Details 128719-Biotin 100 µL
Kappa Light Chain (HCAK1, Ig kappa Chain C Region, IGKC, Immunoglobulin kappa Constant Region, Immunoglobulin kappa Light Chain, Kappa 1 Immunoglobulin Light Chain, Km, MGC111575, MGC62011, MGC72072, MGC88770, MGC88771, MGC88809) (Biotin)
Ask
View Details